FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3200728991> ?p ?o ?g. }

• W3200728991 endingPage "807" @default.
• W3200728991 startingPage "796" @default.
• W3200728991 abstract "Efficacy and safety of anticoagulant treatment for venous thromboembolism (VTE) may vary in patients with different cancer sites. We evaluated the rates of VTE recurrence and major bleeding and the relative efficacy and safety of 6-month treatment with oral apixaban or subcutaneous dalteparin in patients with different cancer sites randomized in the Caravaggio study. Primary cancer was located at gastrointestinal sites in 375 patients (32.5%), lung in 200 (17.3%), breast in 155 (13.4%), genitourinary sites in 139 (12%), gynecological sites in 119 (10.3%), and was hematological in 85 patients (7.4%). Rates of VTE recurrence were 10.9% in patients with gynecological, 8.8% with gastrointestinal, 6.5% with genitourinary, and 5.5% with lung cancer with lower rates in the other sites of cancer. Rates of major bleeding were 7.2% in patients with genitourinary and 4.8% with gastrointestinal cancer, with lower rates in patients with other sites of cancer. The observed absolute risk difference in VTE recurrence in favor of apixaban was 11.9% in patients with gynecological, 5.5% with lung, 3.7% with genitourinary cancer, and 0.6% with gastrointestinal cancer. None of the risk differences was statistically significant. The rates of major bleeding in patients treated with apixaban or dalteparin was similar across patients with different cancer sites. In conclusion, recurrences appear to be more common in patients with gastrointestinal and gynecological cancer and major bleedings in patients with genitourinary and gastrointestinal cancer. Oral apixaban is a valid oral alternative to subcutaneous dalteparin for the treatment of a large spectrum of patients with cancer-associated VTE." @default.
• W3200728991 created "2021-09-27" @default.
• W3200728991 creator A5004599835 @default.
• W3200728991 creator A5007694037 @default.
• W3200728991 creator A5023227285 @default.
• W3200728991 creator A5025841339 @default.
• W3200728991 creator A5026388140 @default.
• W3200728991 creator A5045808371 @default.
• W3200728991 creator A5051513022 @default.
• W3200728991 creator A5054053039 @default.
• W3200728991 creator A5054783539 @default.
• W3200728991 creator A5061711123 @default.
• W3200728991 creator A5064108429 @default.
• W3200728991 creator A5066626384 @default.
• W3200728991 creator A5089208862 @default.
• W3200728991 date "2021-09-16" @default.
• W3200728991 modified "2023-10-16" @default.
• W3200728991 title "Apixaban and Dalteparin for the Treatment of Venous Thromboembolism in Patients with Different Sites of Cancer" @default.
• W3200728991 cites W2028673858 @default.
• W3200728991 cites W2038981426 @default.
• W3200728991 cites W2115019673 @default.
• W3200728991 cites W2225937646 @default.
• W3200728991 cites W2322031839 @default.
• W3200728991 cites W2529667944 @default.
• W3200728991 cites W2550724994 @default.
• W3200728991 cites W2775434460 @default.
• W3200728991 cites W2802130786 @default.
• W3200728991 cites W2885648944 @default.
• W3200728991 cites W2966354200 @default.
• W3200728991 cites W2971121646 @default.
• W3200728991 cites W2972019042 @default.
• W3200728991 cites W2981274404 @default.
• W3200728991 cites W2983084924 @default.
• W3200728991 cites W3013809005 @default.
• W3200728991 cites W3030798067 @default.
• W3200728991 cites W3037161220 @default.
• W3200728991 cites W3100796456 @default.
• W3200728991 cites W3104890556 @default.
• W3200728991 cites W3127460195 @default.
• W3200728991 cites W3141105901 @default.
• W3200728991 doi "https://doi.org/10.1055/s-0041-1735194" @default.
• W3200728991 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34530482" @default.
• W3200728991 hasPublicationYear "2021" @default.
• W3200728991 type Work @default.
• W3200728991 sameAs 3200728991 @default.
• W3200728991 citedByCount "16" @default.
• W3200728991 countsByYear W32007289912022 @default.
• W3200728991 countsByYear W32007289912023 @default.
• W3200728991 crossrefType "journal-article" @default.
• W3200728991 hasAuthorship W3200728991A5004599835 @default.
• W3200728991 hasAuthorship W3200728991A5007694037 @default.
• W3200728991 hasAuthorship W3200728991A5023227285 @default.
• W3200728991 hasAuthorship W3200728991A5025841339 @default.
• W3200728991 hasAuthorship W3200728991A5026388140 @default.
• W3200728991 hasAuthorship W3200728991A5045808371 @default.
• W3200728991 hasAuthorship W3200728991A5051513022 @default.
• W3200728991 hasAuthorship W3200728991A5054053039 @default.
• W3200728991 hasAuthorship W3200728991A5054783539 @default.
• W3200728991 hasAuthorship W3200728991A5061711123 @default.
• W3200728991 hasAuthorship W3200728991A5064108429 @default.
• W3200728991 hasAuthorship W3200728991A5066626384 @default.
• W3200728991 hasAuthorship W3200728991A5089208862 @default.
• W3200728991 hasConcept C121608353 @default.
• W3200728991 hasConcept C126322002 @default.
• W3200728991 hasConcept C133507102 @default.
• W3200728991 hasConcept C141071460 @default.
• W3200728991 hasConcept C2776256026 @default.
• W3200728991 hasConcept C2776301958 @default.
• W3200728991 hasConcept C2778661090 @default.
• W3200728991 hasConcept C2779161974 @default.
• W3200728991 hasConcept C2780638905 @default.
• W3200728991 hasConcept C526805850 @default.
• W3200728991 hasConcept C542804219 @default.
• W3200728991 hasConcept C71924100 @default.
• W3200728991 hasConceptScore W3200728991C121608353 @default.
• W3200728991 hasConceptScore W3200728991C126322002 @default.
• W3200728991 hasConceptScore W3200728991C133507102 @default.
• W3200728991 hasConceptScore W3200728991C141071460 @default.
• W3200728991 hasConceptScore W3200728991C2776256026 @default.
• W3200728991 hasConceptScore W3200728991C2776301958 @default.
• W3200728991 hasConceptScore W3200728991C2778661090 @default.
• W3200728991 hasConceptScore W3200728991C2779161974 @default.
• W3200728991 hasConceptScore W3200728991C2780638905 @default.
• W3200728991 hasConceptScore W3200728991C526805850 @default.
• W3200728991 hasConceptScore W3200728991C542804219 @default.
• W3200728991 hasConceptScore W3200728991C71924100 @default.
• W3200728991 hasIssue "05" @default.
• W3200728991 hasLocation W32007289911 @default.
• W3200728991 hasLocation W32007289912 @default.
• W3200728991 hasOpenAccess W3200728991 @default.
• W3200728991 hasPrimaryLocation W32007289911 @default.
• W3200728991 hasRelatedWork W134396366 @default.
• W3200728991 hasRelatedWork W1839167940 @default.
• W3200728991 hasRelatedWork W2363413836 @default.
• W3200728991 hasRelatedWork W2366058936 @default.
• W3200728991 hasRelatedWork W2372809030 @default.
• W3200728991 hasRelatedWork W2412701647 @default.
• W3200728991 hasRelatedWork W2418548021 @default.

• next